As Biotechnology businesses, Tiziana Life Sciences PLC (NASDAQ:TLSA) and Cambrex Corporation (NYSE:CBM), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.
Earnings and Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Tiziana Life Sciences PLC | N/A | 0.00 | N/A | -0.07 | 0.00 |
Cambrex Corporation | 531.18M | 2.41 | 93.21M | 2.71 | 15.22 |
We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Tiziana Life Sciences PLC and Cambrex Corporation.
Profitability
Table 2 demonstrates the return on equity, return on assets and net margins of Tiziana Life Sciences PLC and Cambrex Corporation.
Net Margins | Return on Equity | Return on Assets | |
Tiziana Life Sciences PLC | 0.00% | 0% | 0% |
Cambrex Corporation | 17.55% | 14.6% | 9% |
Analyst Ratings
The following table delivered below contains the ratings and recommendations for Tiziana Life Sciences PLC and Cambrex Corporation.
Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
Tiziana Life Sciences PLC | 0 | 0 | 0 | 0.00 |
Cambrex Corporation | 0 | 1 | 1 | 2.50 |
On the other hand, Cambrex Corporation’s potential upside is 12.83% and its average price target is $43.
Institutional and Insider Ownership
Institutional investors owned 0.28% of Tiziana Life Sciences PLC shares and 0% of Cambrex Corporation shares. Competitively, 0.7% are Cambrex Corporation’s share owned by insiders.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
Tiziana Life Sciences PLC | -11.37% | -23.74% | 0% | 0% | 0% | -28.86% |
Cambrex Corporation | 0.27% | -5.59% | -14.32% | -37.75% | -19.35% | 9.14% |
For the past year Tiziana Life Sciences PLC had bearish trend while Cambrex Corporation had bullish trend.
Summary
Cambrex Corporation beats Tiziana Life Sciences PLC on 11 of the 11 factors.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.